Valacyclovir hydrochloride [124832-27-5]
Référence T1087-100mg
Conditionnement : 100mg
Marque : TargetMol
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
Valacyclovir hydrochloride
(Synonyms: Valaciclovir hydrochloride, Valaciclovir HCl) Copy Product Info
Valacyclovir hydrochloride (Valaciclovir hydrochloride) is an acyclovir prodrug that, upon metabolism, inhibits viral DNA replication.
Cas No. 124832-27-5
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.88%
Appearance:Solid
Color:White
COA HNMR LCMS
Product Introduction
Valacyclovir hydrochloride AI Summary
Valacyclovir hydrochloride exhibits a broad spectrum of biological activities including the induction of DNA re-replication in normal breast cells and colon adenocarcinoma cells with varying potencies. It specifically inhibits human tyrosyl-DNA phosphodiesterase 1, USP1/UAF1, and PTHR in different cellular environments, both with and without camptothecin (CPT). Additionally, it displays potential to block the entry of the Ebola virus and inhibits sodium fluorescein uptake in OATP1B3 and OATP1B1-transfected CHO cells by 80.91% and 68.57% respectively at 10 μM. In terms of gastrointestinal absorption, Valacyclovir hydrochloride demonstrates significant drug uptake in mouse jejunum (82.0%) and varying permeability across different cell types and pH conditions. It also shows good oral bioavailability in rats (54.0% at 25 mg/kg), with low chemical stability (<5.0%). The compound exhibits no significant inhibition of human BSEP, MRP2, MRP3, and MRP4 transporters with IC50 values greater than 133,000 nM, indicating minimal bioactivity against these targets. Despite assessing antiviral activity against SARS-CoV-2 in different assays, the compound generally shows low to minimal inhibition rates, indicating limited effectiveness against the virus under tested conditions. Moreover, Valacyclovir hydrochloride demonstrates antifungal activity against Candida albicans (3.14% inhibition) and antibacterial activity against various bacteria, including Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Staphylococcus aureus MRSA, with inhibition rates ranging from 6.23% to 17.42%. However, its activity against Cryptococcus neoformans H99 shows a negative inhibition rate (-5.07%). Overall, Valacyclovir hydrochloride possesses multiple bioactive properties with potential implications for treating cancer, viral infections including Ebola, certain bacterial infections, and fungal diseases, while also exhibiting specific inhibitory actions on drug transport processes..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Valacyclovir hydrochloride (Valaciclovir hydrochloride) is an acyclovir prodrug that, upon metabolism, inhibits viral DNA replication. |
| Targets & IC50 | HSV1:2.9 μg/mL (IC50) |
| In vitro | In male CD rats, Valaciclovir was absorbed orally, efficiently metabolized and rapidly distributed. |
| In vivo | Valaciclovir is the L-valine ester of aciclovir, the absorption of which occurs in the intestinal lumen and is converted to the L-valine ester of aciclovir.Valaciclovir inhibits the uptake of dipeptide transporter protein substrates, e.g., cephalosporin. |
| Synonyms | Valaciclovir hydrochloride, Valaciclovir HCl |
| Molecular Weight | 360.80 |
| Formula | C13H20N6O4·HCl |
| Cas No. | 124832-27-5 |
| Smiles | Cl.CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O |
| Relative Density. | 1.55g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 20.4 mg/mL (56.54 mM), Sonication is recommended.  | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 10 mg/mL (27.72 mM), Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.54 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||